Prevention of perinatal transmission of the hepatitis B virus. Outcome of infants in a community prevention program

Am J Dis Child. 1992 Jul;146(7):793-6. doi: 10.1001/archpedi.1992.02160190025012.

Abstract

Objective: To assess the outcome of infants born to hepatitis B surface antigen (HBsAg)-positive mothers who received prenatal and infant care in a large, public health care system.

Design: Follow-up of a cohort of infants born to HBsAg-positive mothers.

Setting: Large, urban hospital providing prenatal care and obstetric services to county health departments.

Participants: Forty-two infants born to HBsAg-positive women.

Interventions: Prenatal testing of women and immunoprophylaxis of infants with hepatitis B immune globulin at birth and hepatitis B vaccine at birth and ages 1 and 6 months.

Results: All 42 infants received hepatitis B immune globulin and the first dose of vaccine. Of forty-one infants (98%) who received the second dose of vaccine, 37 received it by age 4 months. Thirty-two infants (76%) completed the three-dose vaccine series by age 12 months, and 34 infants (81%) completed the series by age 18 months. The rate of completion of the hepatitis B vaccine series was comparable to that of infants receiving the third dose of diphtheria-pertussis-tetanus vaccine. Of 26 infants who completed the hepatitis B vaccine series and had follow-up serologic testing, 24 (92%) had adequate levels of antibody to HBsAg. Only one infant who did not complete the vaccine series had serologic evidence of hepatitis B virus infection. No infant was HBsAg-positive.

Conclusions: Public programs serving urban populations can effectively deliver hepatitis B immunoprophylaxis to infants born to HBsAg-positive mothers.

MeSH terms

  • Adolescent
  • Adult
  • Child Health Services / standards*
  • Child, Preschool
  • Community Health Services / standards*
  • Follow-Up Studies
  • Georgia
  • Hepatitis B / blood
  • Hepatitis B / prevention & control*
  • Hepatitis B / transmission
  • Hepatitis B Surface Antigens / blood
  • Hospitals, Urban
  • Humans
  • Immunization / standards*
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant, Newborn
  • Mass Screening / standards
  • Outcome Assessment, Health Care
  • Program Evaluation
  • Viral Hepatitis Vaccines / administration & dosage
  • Viral Hepatitis Vaccines / therapeutic use

Substances

  • Hepatitis B Surface Antigens
  • Immunoglobulins, Intravenous
  • Viral Hepatitis Vaccines